Scisparc Ltd (SPRC) News & EventsSPRCScisparc Ltd

SciSparc Shifts Focus to Agentic AI Technologies

SciSparc announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision on July 27 to target the Agentic AI market and the announcement on August 26 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies.

Optimi Completes Psychedelic Production and Starts Clinical Trial

In this week's "Psychedelic," The Fly's recurring series focused on psychedelic stock news, The Fly looks back on a production completion, a strategic investment and patent publications.OPTIMI COMPLETES PSILOCYBIN PRODUCTION:Optimi Healthannounced Wednesday the completion and quality release of amanufactured end to end at the company's cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently announced Phase 2 clinical trial of psilocybin-assisted therapy in the treatment of major depressive disorder and commercial customers in Australia. This Health Canada-authorized trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027. Data from the trial are intended to assess the safety and efficacy of psychedelic-assisted therapy in the hope of building the necessary evidentiary base to support registration in Canada and other jurisdictions. The same batch will also supply the company's Australian customer base of licensed clinics, where 5mg psilocybin capsules are prescribed to patients with treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme, with reimbursement from public and private payers."Since 2025, Optimi has supplied this psilocybin product commercially to licensed clinics in Australia, where it is prescribed and reimbursed for treatment-resistant depression," said Dane Stevens, CEO. "We are excited to be collecting our own clinical data on the same product in our Health Canada-approved Phase 2 clinical trial for major depressive disorder. One drug, two indications with significant unmet need, one batch serving both. Because we manufacture, encapsulate and release-test within our own licensed facility, the trial product and the commercial product are the same formulation from the same batch, and the Chemistry, Manufacturing and Controls file that supports registration is already ours."Optimi also announced Tuesday the appointment of Michael Blough as Chief Clinical Development Officer. In this newly created position, he will oversee Optimi's clinical development strategy and related operations. Blough is a medical researcher with more than 20 years of experience directing research programs spanning bench science, pre-clinical studies, and clinical trials.PSYENCE BIOMED ANNOUNCES IBOGAINE INVESTMENT:Psyence Biomedicalannounced Wednesday that it has agreed to make atogether with a value-matched share exchange between the two companies. The transactions are intended to support the scientific, manufacturing and development capabilities required for Psyence BioMed's planned U.S. ibogaine program. TIRC, registered and headquartered in Texas, has been established to provide a dedicated corporate structure through which the company can coordinate its planned U.S. regulatory, clinical and development activities involving pharmaceutical-grade ibogaine. The company is currently evaluating the feasibility and design of a potential ibogaine clinical trial in Texas. Any clinical program would be subject to protocol development, regulatory review and authorization, institutional approvals, funding, site selection and other customary requirements."Access to pharmaceutical-grade ibogaine is fundamental to the U.S. program we are planning," said Jody Aufrichtig, CEO. "Our investment in PsyLabs, together with the share exchange, is intended to align Psyence BioMed more closely with the manufacturing and supply capabilities we believe a regulated clinical program will require, while TIRC provides the dedicated U.S. structure through which we intend to advance that program. Our objective is to advance this program responsibly, supported by rigorous clinical research and pharmaceutical-grade manufacturing."CLEARMIND REPORTS PUBLICATION OF THREE PATENT APPLICATIONS:Clearmind Medicineannounced Wednesday thecovering novel proprietary combinations of lysergic acid diethylamide, ketamine and ibogaine with N-acylethanolamines, such as palmitoylethanolamide. The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression, post-traumatic stress disorder pain and substance use disorders. The publications expand the intellectual property generated through Clearmind's ongoing collaboration with NeuroThera Labs, a subsidiary of SciSparc, under which NeuroThera's PEA technology is integrated into Clearmind's psychedelic-derived therapeutic programs."The publication of these patents come at a significant time as clinical and regulatory interest in LSD, ketamine and ibogaine continues to receive growing recognition and support for their therapeutic potential. Clearmind believes its combination approach may offer the potential for an effective and safer treatment paradigm, aiming to achieve therapeutic benefits at lower doses while preserving efficacy. By reducing the dose required to achieve the intended pharmacological effect, this approach may support improved tolerability while maintaining therapeutic potential," said Adi Zuloff‑Shani, CEO.FILAMENT DELIVERS PEX010 TO BHRI:Rhelion Life Sciencesannounced Monday that Bruyere Health Research Institute in Ottawa hasa patented, standardized, GMP manufactured botanical psilocybin drug candidate, from Filament for the Phase 3 trial titled "Psilocybin Microdose for Psychological and Existential Distress in Palliative Care: A Multi-Site Phase 3 Double-Blind, Placebo-Controlled, Parallel-Arm Clinical Trial". The trial will compare microdose psilocybin with placebo in people with advanced illness who are experiencing psychological distress, such as depression, anxiety and loss of meaning. It plans to enroll 120 participants from inpatient, outpatient and community palliative care settings across seven sites in Canada. Participants take small daily doses that do not cause hallucinations and do not require accompanying psychotherapy, an approach designed to be practical for patients near the end of life. Bruyère Health Research Institute is the sponsor of the trial. The Phase 3 trial builds on the Phase I/II PSYCHED-PAL study, sponsored by The Ottawa Hospital Research Institute, which also used PEX010. Results published in Palliative Medicine in 2026 found that microdose psilocybin was safe, feasible and potentially effective for psychological distress in a palliative setting, with participants reporting improvements in depression, anxiety, demoralization and well-being and no serious adverse effects.The company also announced Tuesday that the Canadian Intellectual Property Office has issued a new patent to Filament, titled "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation."BARCLAYS SAYS HELUS SELLOFF 'A BUYING OPPORTUNITY":Barclays said it viewed the selloff Friday in shares of Helus Pharmaas a buying opportunity. The firm initiated the stock on Friday morning withBarclays said its initiation was not intended to serve as a preview of the Phase 3 APPROACH study of HLP003 in adjunctive treatment of MDD in isolation. The 7-8 point range discussed in the initiation "was neither our base-case expectation nor a required outcome for our $35 price target," the analyst said. The firm said it represented an illustrative extrapolation of the Phase 2 HLP003 result using attenuation observed in selected Phase 2-to-Phase 3 precedents.OTHER PSYCHEDELIC STOCKS:Publicly-traded companies in the space include Grey Matters Health, BetterLife, Bright Minds Biosciences, Compass Pathways, Definium Therapeutics, Eli Lilly, Enveric Biosciences, GH Research, Incannex, MIRA Pharmaceuticals, NRx Pharmaceuticals, Numinus Wellness, Pasithea Therapeutics, PharmAla Biotech, PharmaTher, Revive Therapeutics, Sibannacand Silo Pharma.

SciSparc Expands U.S. IP Portfolio with Clearmind Collaboration

SciSparc (SPRC) announced that NeuroThera Labs highlighted the expansion of the U.S. intellectual property, IP, portfolio through its ongoing collaboration with Clearmind Medicine (CMND). As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide, ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide, NeuroThera's proprietary technology. The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.